These findings provide further support for the addition of nivolumab to chemotherapy as a standard-of-care first-line treatment option for patients with non-HER2-positive advanced GC/GEJC/EAC and offer new data to assist clinical decision-making of physicians determining the ideal treatment strategy for these patients. This evidence concerns the gene ERBB2 and gastric cancer.